SCHEMBL1635633

SCHEMBL1635633

CC(=O)OC1C[C@@]2(C)C(=CC1=O)C(C)=C[C@H]1[C@@H]3CC[C@H](C(C)=O)[C@@]3(C)CC[C@@H]12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 2/20 0.48
CYP3A4 P08684 6/20 0.47
PGR P06401 4/20 0.47
AR P10275 4/20 0.47
ALDH1A1 P00352 4/20 0.47
CHRM1 P11229 3/20 0.47
CYP2C19 P33261 2/20 0.47
ADRA1A P35348 2/20 0.47
TBXA2R P21731 1/20 0.47
LMNA P02545 5/20 0.46
CYP2C9 P11712 4/20 0.46
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
HIF1A Q16665 3/20 0.46
MAPK1 P28482 3/20 0.46
ABCB11 O95342 2/20 0.46
NR3C1 P04150 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3028086 1.00 CYP19A1 (0.48) CYP19A1CYP3A4PGRARALDH1A1
SCHEMBL369752 0.81 CYP3A4 (0.66) CYP19A1CYP3A4PGRARALDH1A1
SCHEMBL29882740 0.81 CYP3A4 (0.66) CYP19A1CYP3A4PGRARALDH1A1
SCHEMBL18402585 0.81 CYP3A4 (0.66) CYP19A1CYP3A4PGRARALDH1A1
SCHEMBL13981881 0.81 CYP3A4 (0.66) CYP19A1CYP3A4PGRARALDH1A1
SCHEMBL10896735 0.81 CYP3A4 (0.66) CYP19A1CYP3A4PGRARALDH1A1
SCHEMBL1635631 0.77 CYP3A4 (0.44) CYP19A1CYP3A4PGRARALDH1A1
SCHEMBL4753154 0.76 ALDH1A1 (0.67) CYP19A1CYP3A4PGRARALDH1A1
SCHEMBL4751113 0.74 SERPINA6 (0.67) CYP19A1CYP3A4PGRARALDH1A1
SCHEMBL1635637 0.73 ALDH1A1 (0.65) CYP19A1CYP3A4PGRARALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932382-B2 Amide substituted heterocylic compound; anticarcinogen; inducing apoptotic cell death, sensitizing cells to inducers of apoptosis THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2011-04-26 US disclosed
US-20090082445-A1 GOSSYPOL CO-CRYSTALS AND THE USE THEREOF THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2009-03-26 US disclosed
WO-2008148473-A2 METHOD FOR THE PRODUCTION OF 17 ALPHA-ACETOXY-6-METHYLENEPREGN-4-ENE-3,20-DIONE, MEDROXYPROGESTERONE ACETATE, AND MEGESTROL ACETATE BAYER SCHERING PHARMA AG (DE) 2008-12-11 WO disclosed
US-20080269140-A1 Conformationally Constrained Smac Mimetics and the Uses Thereof THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2008-10-30 US disclosed
WO-2002026325-A9 RESTORATION OF PERTURBED BARRIER FUNCTION BY APPLICATION OF ANTIANDROGENS UNIV CALIFORNIA (US) 2003-02-13 WO disclosed
WO-2002026325-A2 RESTORATION OF PERTURBED BARRIER FUNCTION BY APPLICATION OF ANTIANDROGENS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2002-04-04 WO disclosed
EP-0479867-A1 COMPOSITIONS USEFUL AS CONTRACEPTIVES IN MALES. COHEN MICHAEL (NL) 1992-04-15 EP disclosed
WO-1991000095-A1 COMPOSITIONS USEFUL AS CONTRACEPTIVES IN MALES COHEN MICHAEL (NL) 1991-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269140-A1 Conformationally Constrained Smac Mimetics and the Uses Thereof BID, API5, BIRC3 CYP19A1 4669/4885CYP3A4 4804/4885PGR 4426/4885
US-20090082445-A1 GOSSYPOL CO-CRYSTALS AND THE USE THEREOF BAX, BCL2, CASP8 CYP19A1 3440/4885CYP3A4 3951/4885PGR 4476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.